Molbio Diagnostics IPO Launches Today with 15% GMP: Check Price Band and Decide on Subscription!

The Molbio Diagnostics IPO, which opens for subscription today, August 10, 2026, is attracting significant attention in the grey market with a premium of 15%, indicative of strong market expectations regarding its listing performance. Analysts recommend subscribing to the IPO based on its valuations that align well with industry benchmarks and the fact that it is priced at a discount to the average P/E multiple of 64.9x for similar companies. This IPO comprises a fresh issue of shares worth Rs 200 crore and an Offer for Sale (OFS) amounting to Rs 739.70 crore.

The share price band has been set between Rs 768 and Rs 807, and the issue is anticipated to generate approximately Rs 939.70 crore at the upper end of the range. Prominent existing shareholders, including Exxora Trading LLP and India Business Excellence Fund III, will participate in the OFS, selling a total of over 40 lakh shares. Notably, the company raised Rs 281.5 crore from anchor investors before the IPO, successfully allotting shares at the upper price band.

Molbio Diagnostics plans to utilize the IPO proceeds primarily to bolster its infrastructure and enhance R&D capabilities, with a projected Rs 125.12 crore allocated for building a new research facility. Additionally, Rs 80.81 crore is earmarked for upgrading manufacturing equipment in Goa and Visakhapatnam. The company reported a robust financial performance with a 42% increase in total income to Rs 1,455 crore in FY26, alongside an 18% rise in profit after tax to Rs 164 crore, underscoring its strong growth trajectory in the diagnostics market.

The overall sentiments surrounding the IPO are positive, with recommendations emphasizing its attractive valuations and growth potential in a thriving sector. With a strong portfolio of rapid diagnostic solutions capable of addressing various healthcare challenges, Molbio Diagnostics is positioned well to capitalize on increasing demand, making this public offering an appealing opportunity for investors seeking scalable growth in the healthcare domain.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)